Krystal Biotech (KRYS) – Research Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Krystal Biotech (NASDAQ: KRYS):

• 9/24/2026 – Krystal Biotech was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 9/24/2026 – Krystal Biotech is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $441.00 price target on the stock.
• 9/24/2026 – Krystal Biotech is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $441.00 price target on the stock.
• 9/23/2026 – Krystal Biotech was upgraded by William Blair to “strong-buy”.
• 9/21/2026 – Krystal Biotech had its price target raised by Bank of America Corporation from $392.00 to $400.00. They now have a “buy” rating on the stock.
• 8/18/2026 – Krystal Biotech was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
• 8/14/2026 – Krystal Biotech is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $400.00 price target on the stock.
• 8/14/2026 – Krystal Biotech is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $400.00 price target on the stock.
• 8/4/2026 – Krystal Biotech had its price target raised by Citigroup Inc. from $378.00 to $386.00. They now have a “buy” rating on the stock.
• 8/3/2026 – Krystal Biotech was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 8/3/2026 – Krystal Biotech was upgraded by Chardan Capital to “strong-buy”.

Insiders Place Their Bets

In related news, Director Dino A. Rossi sold 25,000 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the sale, the director directly owned 50,000 shares of the company’s stock, valued at $16,456,000. This represents a 33.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the transaction, the insider owned 1,302,145 shares in the company, valued at approximately $467,886,741.40. The trade was a 1.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is currently owned by corporate insiders.

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors designed to deliver functional genes to targeted tissues, with the goal of treating diseases caused by genetic mutations.

Krystal Biotech’s lead product, VYJUVEK (beremagene geperpavec-svdt), is a topical gene therapy approved in the United States for the treatment of wounds in patients with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering.